CSB 2.32(1)(1)Section 961.14 (7) (q), Stats., is created to read:
Section 961.14 (7) (q) N - benzylpiperazine, commonly known as “BZP."
CSB 2.32 History History: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07.
CSB 2.33 CSB 2.33 Addition of alpha-methyltryptamine (AMT) to schedule I.
CSB 2.33(1)(1)Section 961.14 (4) (wi), Stats., is created to read:
Section 961.14 (4) (wi) Alpha-methyltryptamine, commonly known as “AMT";
CSB 2.33 History History: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07.
CSB 2.34 CSB 2.34 Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT).
CSB 2.34(1)(1)Section 961.14 (4) (wj), Stats., is created to read:
Section 961.14 (4) (wj) 5-methoxy-N, N-diisopropyltryptamine, commonly known as “5-MeO-DIPT";
CSB 2.34 History History: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07.
CSB 2.35 CSB 2.35 Addition of lisdexamfetamine to schedule II.
CSB 2.35(1)(1)Section 961.16 (5) (e), Stats., is created to read:
Section 961.16 (5) (e) Lisdexamfetamine, commonly known as “Vyvanse TM."
CSB 2.35 History History: CR 10-112: cr. Register April 2011 No. 664, eff. 5-1-11.
CSB 2.36 CSB 2.36 Addition of tramadol to schedule IV. Section 961.20 (4) (e), Stats., is created to read:
Section 961.20 (4) (e) Tramadol, including any of its isomers and salts of isomers.
CSB 2.36 History History: cr. Affirmative action order under s. 968.11 (4), Stats., Register August 2014 No. 704, eff. 9-1-14; CR 15-008: cr. Register October 2015 No. 718, eff. 11-1-15.
CSB 2.37 CSB 2.37 Rescheduling of hydrocodone combination products. Sections 961.18 (5) (c) and (d), Stats., are repealed.
CSB 2.37 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11-1-14; CR 15-007: cr. Register October 2015 No. 718, eff. 11-1-15.
CSB 2.38 CSB 2.38 Addition of suvorexant to schedule IV. Section 961.20 (2) (mr), Stats., is created to read:
Section 961.20 (2) (mr) Suvorexant.
CSB 2.38 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11-1-14; CR 15-009: cr. Register October 2015 No. 718, eff. 11-1-15.
CSB 2.39 CSB 2.39 Exclusion of naloxegol. Section 961.16 (2) (a) (intro.), Stats., is amended to read:
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.39 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2015 No. 711B, eff. 4-1-15; CR 15-068: cr. Register August 2016 No. 728, eff. 9-1-16.
CSB 2.40 CSB 2.40 Exclusion of [123I]ioflupane. Section 961.16 (2) (b), Stats., is amended to read:
(b) Coca leaves and any salt, compound, derivative or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [123I]Ioflupane is excluded from this paragraph. The following substances and any of their salts, esters, isomers and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.40 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2015 No. 718A3, eff. 10-19-15; correction made under s. 35.17, Stats., Register October 2015 No. 718; CR 16-060: cr. Register May 2017 No. 737, eff. 6-1-17.
CSB 2.41 CSB 2.41 Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl. Sections 961.14 (2) (eu) and (ey) are created to read:
961.14 (2) (eu) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)
(ey) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)
CSB 2.41 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2016 No. 728, eff. 7-18-16; CR 16-081: cr. Register July 2017 No. 739, eff. 8-1-17.
CSB 2.42 CSB 2.42 Scheduling of furanyl fentanyl. Section 961.14 (2) (ne) is created to read:
961.14 (2) (ne) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).
CSB 2.42 History History: EmR1626: emerg. cr., eff. 9-1-16; CR 16-059: cr. Register May 2017 No. 737, eff. 6-1-17.
CSB 2.43 CSB 2.43 Addition of brivaracetam to schedule V. Section 961.22 (6), Stats., is created to read:
961.22 (6) BRIVARACETAM. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide), including its salts, isomers or salts of isomers.
CSB 2.43 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register September 2016 No. 729, eff. 9-26-16; CR 17-009: cr. Register July 2017 No. 739, eff. 8-1-17.
CSB 2.44 CSB 2.44 Addition of thiafentanil to schedule II. Section 961.16 (3) (zx), Stats., is created to read:
961.16 (3) (zx) Thiafentanil.
CSB 2.44 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2016 No. 730, eff. 10-3-16; CR 17-007: cr. Register July 2017 No. 739, eff. 8-1-17.
CSB 2.45 CSB 2.45 Addition of AB-FUBINACA and ADB-PINACA to schedule I. Section 961.14 (4) (tb) 32. and 33., Stats., is created to read:
961.14 (4) (tb) 32. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as AB-FUBINACA.
33. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as ADB-PINACA.
CSB 2.45 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2016 No. 730, eff. 10-10-16; CR 17-008: cr. Register July 2017 No. 739, eff. 8-1-17.
CSB 2.46 CSB 2.46 Addition of acetyl fentanyl to schedule I. Section 961.14 (2) (ae), Stats., is created to read:
961.14 (2) (ae) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide).
CSB 2.46 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11-21-16; CR 17-021: cr. Register November 2017 No. 743, eff. 12-1-17.
CSB 2.47 CSB 2.47 Addition of AH-7921 to schedule I. Section 961.14 (2) (aj), Stats., is created to read:
961.14 (2) (aj) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide).
CSB 2.47 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11-21-16; CR 17-023: cr. Register November 2017 No. 743, eff. 12-1-17.
CSB 2.48 CSB 2.48 Addition of eluxadoline to schedule IV. Section 961.20 (4) (cm), Stats., is created to read:
961.20 (4) (cm) Eluxadoline, including any of its isomers, and salts of isomers.
CSB 2.48 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11-21-16; CR 17-022: cr. Register November 2017 No. 743, eff. 12-1-17.
CSB 2.49 CSB 2.49 Addition of U-47700 to schedule I. Section 961.14 (2) (z), Stats., is created to read:
961.14 (2) (z) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide).
CSB 2.49 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2016 No. 732, eff. 12-19-16; CR 17-020: cr. Register November 2017 No. 743, eff. 12-1-17.
CSB 2.50 CSB 2.50 Addition of AB-CHMINACA, AB-PINACA and THJ-2201 to schedule I. Section 961.14 (4) (tb) 34., 35., and 36., Stats., are created to read:
961.14 (4) (tb) 34. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as AB-CHMINACA.
35. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as AB-PINACA).
36. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone, commonly known as THJ-2201.
CSB 2.50 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2017 No. 736, eff. 3-27-17; correction in (intro.) made under s. 35.17, Stats., Register April 2017 No. 736.
CSB 2.51 CSB 2.51 Addition of MAB-CHMINACA to schedule I. Section 961.14 (4) (tb) 37., Stats., is created to read:
961.14 (4) (tb) 37. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as MAB-CHMINACA or ADB-CHMINACA.
CSB 2.51 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2017 No. 736, eff. 3-27-17.
CSB 2.52 CSB 2.52 Addition of 4-MePPP and a-PBP to schedule I. Section 961.14 (7) (L) 32. and 33., Stats., is created to read:
961.14 (7) (L) 32. 4-methyl-alpha-pyrrolidinopropiophenone, commonly known as 4-MePPP.
33. Alpha-pyrrolidinobutiophenone, commonly known as a-PBP.
CSB 2.52 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2017 No. 736, eff. 4-10-17.
CSB 2.53 CSB 2.53 Scheduling of acryl fentanyl. Section 961.14 (2) (ai), Stats., is created to read:
961.14 (2) (ai) Acryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-2-propenamide);
CSB 2.53 Note Note: Section 961.14 (2) (ai), Stats., was renumbered to s. 961.14 (2) (nd) 3. by 2017 Wis. Act 60.
CSB 2.53 History History: EmR1710: emerg. cr., eff. 5-2-17; CR 17-040: cr. Register November 2017 No. 743, eff. 12-1-17; correction made under s. 35.17, Stats., Register November 2017 No. 743.
CSB 2.54 CSB 2.54 Addition of oral solutions containing dronabinol to schedule II. Section 961.16 (10), Stats., is created to read:
961.16 (10) (a) Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution in a drug product approved by the U.S. food and drug administration.
CSB 2.54 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2017 No. 737, eff. 5-15-17; CR 18-055: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.55 CSB 2.55 Addition of 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA to schedule I. Section 961.14 (4) (tb) 38., 39., 40., 41., and 42., Stats., is created to read:
961.14 (4) (tb) 38. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-ADB.
39. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as 5F-AMB.
40. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as ADB-FUBINACA.
41. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate commonly known as MDMB-CHMICA.
42. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-FUBINACA.
CSB 2.55 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2017 No. 737, eff. 5-15-17.
CSB 2.56 CSB 2.56 Addition of 4-fluoroisobutyryl fentanyl to schedule I. Section 961.14 (2) (nc), Stats., is created to read:
961.14 (2) (nc) 4-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.56 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2017 No. 738, eff. 6-12-17.
CSB 2.57 CSB 2.57 Scheduling of cyclopropyl fentanyl. Section 961.14 (2) (nd) 10d., Stats., is created to read:
961.14 (2) (nd) 10d. Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
CSB 2.57 History History: EmR 1716: emerg. cr. eff. 9-8-17; CR 17-0785: cr. Register July 2018 No. 751, eff. 8-1-18; corrections made under s. 35.17, Stats., Register July 2018 No. 751.
Loading...
Loading...
Published under s. 35.93, Stats. Updated on the first day of each month. Entire code is always current. The Register date on each page is the date the chapter was last published.